ProUroCare Medical PUMD · USD

Its shares trade under the ticker PUMD. It has been listed since 28 May 2002.

ProUroCare Medical, Inc. engages in the development of products for the detection and characterization of male prostate disease. The company is headquartered in Eden Prairie, Minnesota. The company went IPO on 2002-05-28. The firm is focused on its product, prostate mechanical imaging device called the ProUroScan System. The ProUroScan is an imaging system that is designed to produce an elasticity image of the prostate as an adjunctive aid in visualizing and documenting abnormalities of the prostate that have been detected by a digital rectal examination (DRE). The ProUroScan uses an array of sensors mounted on a rectal probe, a central processing unit, and software and image construction algorithms to provide a real time color image of abnormalities in the prostate. In addition, it provides mechanical or elasticity imaging, which refers to a non-invasive analysis of tissue movement and displacement. The Company’s product also provides two-and three-dimensional prostate images.

Figures and description from our data supplier, not checked against the company's own report.

• James DavisChairman of the Board, since 2010
• Stanton MyrumInterim Chief Executive Officer, Director, since 2013
• Alan ShulerChief Financial Officer, Secretary
• David KaysenDirector
• Scott SmithIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.